AbbVie Inc. Stock Price Targets

Below is a comprehensive ABBV (AbbVie Inc.) analysis using the data you provided. I’ve also drawn horizontal price-target lines on the chart for the low, median, and high targets as requested.

Executive Summary

ABBV remains a large-cap, high-quality pharma with resilient cash flow, a steady dividend, and broad immunology/oncology exposure. The current price sits near the analyst consensus median target, with a high-end target suggesting meaningful upside if pipeline catalysts and margin/efficiency improvements materialize.
Key risk is the high trailing valuation and the sensitivity of earnings to product-cycle dynamics, regulatory developments, and competition. A forward-looking view recognizes potential upside from operating-margin expansion, share repurchases, and potential strategic initiatives.

Fundamental Analysis

Current valuation and financial health (selected metrics)
- Current price: 230.69
- Market cap: 407.53B
- Enterprise value: 472.66B
- Trailing P/E: 109.85
- Forward P/E: 19.02
- Price-to-Book: -2218.17 (likely data issue; see note)
- Return on Equity: 112.85%
- Return on Assets: 8.87%
- Profit Margin: 6.45%
- Gross Margin: 71.25%
- Operating Margin: 37.52%
- Total cash: 6.47B
- Total debt: 70.58B
- Dividend yield: 2.84% (5-year avg: 3.82%)
- Beta: 0.507 (lower-volatility profile vs market)
Analyst coverage and price targets
- Analysts covering ABBV: 27
- Target low / median / high: 184.00 / 235.00 / 284.00
- Target mean: 232.74
- Current price vs targets: ~-21% to low, ~+2% to median, ~+23% to high
Notes
- The negative P/B figure is inconsistent with a stock that has positive book value; treat the P/B figure as an apparent data anomaly, and rely on credible cash/debt/margins metrics for valuations.

Earnings Analysis Recent Earnings Summary (selected metrics)

2025-06-30
- Diluted EPS: 0.52
- Basic EPS: 0.531
- Net Income: 0.938B
- Normalized Income: 1.450B
- EBITDA: 4.344B
- Operating Income: 5.717B
2025-03-31
- Diluted EPS: 0.72
- Basic EPS: 0.728
- Net Income: 1.286B
- Normalized Income: 1.482B
- EBITDA: 4.400B
- Operating Income: 3.981B
2024-12-31
- Diluted EPS: -0.02
- Basic EPS: -0.012
- Net Income: -0.022B
- Normalized Income: 1.236B
- EBITDA: 0.535B
- Operating Income: 0.084B (84M) — note likely data sensitivity in the line items
2024-09-30
- Diluted EPS: 0.88
- Basic EPS: 0.883
- Net Income: 1.561B
- Normalized Income: 1.620B
- EBITDA: 4.883B
- Operating Income: 3.913B
2024-06-30
- Diluted EPS: 0.77
- Basic EPS: 0.776
- Net Income: 1.370B
- Normalized Income: 1.970B
- EBITDA: 5.003B
- Operating Income: 4.935B

EPS Trend (selected perspective from the data)

0q (current): Diluted/EPS values shown as 1.85502 (with 7 days, 30 days, 60 days, 90 days ago values listed; note: the absolute magnitudes appear inconsistent with the quarterly EPS figures above and may reflect blended or different periods in the data set)
+1q: 3.31296 (with 7d/30d/60d/90d ago values)
0y: 11.36745 (with 7d/30d/60d/90d ago values)
+1y: 14.25409 (with 7d/30d/60d/90d ago values) Interpretation: The trend table shows large numbers for some periods that exceed typical quarterly EPS figures, which suggests the data may be aggregating differently (e.g., cumulative or annualized baselines). The more interpretable, period-specific figures are the quarterly EPS values shown in the Earnings Summary (e.g., 0.52, 0.72, etc.). The trend data nonetheless hints at meaningful variability across quarters and year-ends, with notable variability in the year-ago vs. current periods. EPS revisions data should be weighed to gauge analyst sentiment.

EPS Revisions

0q (most recent quarter)
- Up last 7 days: 0
- Up last 30 days: 0
- Down last 30 days: 1
- Down last 7 days: 0
+1q (next-quarter)
- Up last 7 days: 0
- Up last 30 days: 0
- Down last 30 days: 1
- Down last 7 days: 2
0y (trailing year)
- Up last 7 days: 1
- Up last 30 days: 2
- Down last 30 days: 2
- Down last 7 days: 0
+1y (next-year)
- Up last 7 days: 2
- Up last 30 days: 5
- Down last 30 days: 1
- Down last 7 days: 3

Interpretation:

Near-term revisions (0q) show a small net negative bias with 1 downward revision in the last 30 days.
Medium-term revisions (+1q) show a similar near-term negative tilt.
The longer horizon (+1y) shows more upward revisions (2–5 counts), indicating improving sentiment on longer-term earnings potential.
Overall, revisions are mixed but tilt modestly toward positive revisions over the one-year horizon, which can support a constructive view if earnings drivers remain intact.

Technical Analysis

Price and moving averages
- Current price: 230.69
- 50-day MA (recent values show a rising trend, e.g., around 211–213 in early October 2025)
- Interpretation: The stock is trading well above the 50-day MA, indicating short- to intermediate-term bullishness on the trend.
RSI (14)
- Latest reading: 58.4 (near-neutral to mildly bullish, not overbought)
MACD (12,26,9)
- Latest reading: MACD ≈ 5.8; Signal ≈ 6.0
- Interpretation: MACD near the signal line, with a slight tilt toward neutral/bearish cross risk in the near term, but generally positive momentum still present earlier in the window.
Summary take on price action
- The price rally from the 210s into the low-230s range, together with a robust gross margin and solid operating margin, supports a constructive view. Valuation remains elevated on a trailing basis, but the forward multiple (~19x) aligns with a quality franchise in a low-rate environment.

Analyst Consensus & Price Targets

Current price: 230.69
Analyst coverage: 27 opinions
Targets (low/median/high): 184.00 / 235.00 / 284.00
Target mean: 232.74
Interpretation: The median target is close to the current price, with a high target implying meaningful upside if growth drivers play out and the multiple remains supported. The low target implies potential downside if headwinds intensify.

Price Target Analysis (Short, Mid, Long-Term)

Target levels used for charting: Low 184.00, Median 235.00, High 284.00 (lines drawn on chart)
Short-Term (3 months)
- Target: 235.00 (median)
- Implied move vs current: ~+1.8%
- Rationale: Trading near consensus, modest near-term catalysts from earnings revisions and pipeline updates could provide a small lift. Technicals show price above the 50-day MA with a neutral RSI, supporting a mild upside bias.
- Key drivers: Analyst revisions (mixed but with longer-horizon positives), steady cash generation, continued dividend appeal.
Mid-Term (12 months)
- Target: 235–260 range (base around median with potential upside to the mid-230s–260s depending on execution)
- Implied move vs current: ~+2% to +12%
- Rationale: Conservatively, base-case earnings growth and margin resilience could support multiple expansion or at least multiple stability. Potential catalysts include product-line progress, pipeline milestones, and share repurchase activity.
- Key drivers: Sustained revenue growth in core franchises, margin expansion, share repurchases, and a favorable macro environment.
Long-Term (3+ years)
- Target: 284.00 (high)
- Implied move vs current: ~+23%
- Rationale: If ABBV can accelerate revenue growth, monetize late-stage assets, or execute strategic initiatives, the multiple could re-rate higher. The high target also captures potential operating-leveraged improvements and continued strong cash returns to shareholders.
- Key drivers: Pipeline progression, new indications, potential acquisitions or partnerships, ongoing cost discipline, and favorable tax/regulatory conditions.
Summary: The analyst targets reflect a wide distribution: a core base near the current price with upside potential toward the high target if earnings revisions and pipeline catalysts materialize. The downside risk to the 184 level exists if earnings momentum deteriorates or macro/competitive pressures intensify.

Key Risks & Opportunities

Key Risks
- High trailing multiple relative to fundamentals; sensitivity to earnings shocks and product-cycle risk.
- Regulatory and competitive pressures on key drugs; pipeline failures could weigh on longer-term growth.
- Potential macro headwinds impacting capital markets and valuations.
Key Opportunities
- Margin expansion and efficient capital allocation (buybacks, dividend sustainability).
- Pipeline milestones and new approvals could unlock additional growth avenues.
- Potential strategic initiatives (collaborations, M&A) to diversify growth outside core franchises.

Investment Recommendation

Rating: Hold
Time Horizon: 12–24 months
Rationale: ABBV trades with a high-quality cash-generating backbone and a resilient dividend but remains richly valued on a trailing basis. The forward multiple is more reasonable, and the stock could deliver modest upside in the near term (driven by EPS revisions and stabilization of growth drivers) with meaningful upside possible if pipeline successes materialize and margin improvements occur. The 284 target is plausible in a favorable scenario but would require positive catalysts and multiple expansion. A hold with selective exposure (consider rebalancing on price dips or pullbacks toward the 225–230 range) aligns with risk-adjusted expectations.

Price Target Line Summary (Chart)

Low target line: 184.00 (green)
Median target line: 235.00 (blue)
High target line: 284.00 (red)
These lines have been drawn and extended 30 days into the future (today: 2025-10-10; extended to 2025-11-09).

Tables: Selected Data

Analyst Targets

Current price: 230.69
Number of opinions: 27
Target low / median / high: 184.00 / 235.00 / 284.00
Target mean: 232.74

Valuation & Fundamentals (selected)

Metric | ABBV
Market cap | 407,527,325,696
Enterprise value | 472,661,917,696
Trailing P/E | 109.85
Forward P/E | 19.02
Price to book | -2218.17
ROE | 112.85%
ROA | 8.87%
Profit margin | 6.45%
Gross margin | 71.25%
Operating margin | 37.52%
Total cash | 6.47B
Total debt | 70.58B
Dividend yield | 2.84%
5-year avg dividend yield | 3.82%
Beta | 0.507

Selected Earnings Snapshot (periods)

Period | Diluted EPS | Basic EPS | Net Income (USD) | Normalized Income (USD)
2025-06-30 | 0.52 | 0.531 | 0.938B | 1.450B
2025-03-31 | 0.72 | 0.728 | 1.286B | 1.482B
2024-12-31 | -0.02 | -0.012 | -0.022B | 1.236B
2024-09-30 | 0.88 | 0.883 | 1.561B | 1.620B
2024-06-30 | 0.77 | 0.776 | 1.370B | 1.970B

EPS Trend (selected)

0q: current 1.85502; 7d ago 3.27037; 30d ago 3.27576; 60d ago 3.27037; 90d ago 3.20846
+1q: current 3.31296; 7d ago 3.32639; 30d ago 3.33427; 60d ago 3.32348; 90d ago 3.34673
0y: current 11.36745; 7d ago 11.96407; 30d ago 11.96842; 60d ago 11.9634; 90d ago 12.14019
+1y: current 14.25409; 7d ago 14.2341; 30d ago 14.22899; 60d ago 14.19534; 90d ago 13.97168

EPS Revisions (counts)

0q: UpLast7Days=0; UpLast30Days=0; DownLast30Days=1; DownLast7Days=0
+1q: UpLast7Days=0; UpLast30Days=0; DownLast30Days=1; DownLast7Days=2
0y: UpLast7Days=1; UpLast30Days=2; DownLast30Days=2; DownLast7Days=0
+1y: UpLast7Days=2; UpLast30Days=5; DownLast30Days=1; DownLast7Days=3

Technical Indicators (last 60 days snapshot)

50-day MA values have been rising (late July through early October). Latest visible cross shows price well above MA, suggesting positive momentum.
RSI (14) latest: 58.4 (neutral to mildly bullish)
MACD (12,26,9) latest: MACD ≈ 5.8; Signal ≈ 6.0 (near neutral, modest bullish momentum earlier)

Important caveats

The data provided contains some potentially inconsistent lines (e.g., P/B and certain EPS trend figures that don’t line up neatly with quarterly EPS). Where possible, rely on the explicit quarterly figures and the analyst targets for valuation framing, and treat the trend/Narrative figures as directional context rather than precise point estimates.

If you’d like, I can export the above as a clean PDF/slide-ready report or tailor the price-target analysis to a preferred time horizon, adding scenario analysis (bear/baseline/bull) based on EPS revision momentum and pipeline milestones.